
Patients Using Electronic Diaries to Monitor Migraines
Clinvest was approached by one of the largest pharmaceutical companies to "create and manage a [Mental Efficiency and Workload Test] for 500 subjects in a migraine trial occurring in 50 sites across the United States." This will be the first time cognitive processing time will be tested in a major migraine study.
During the study, participants will use LogPad to record when they have a migraine, how long the migraine lasts, and its severity; keep track of their quality of sleep; and take electronic tests used to “measure their ability to perform simple calculations and react appropriately to stimuli.” The study will evaluate “the effect of barbiturates on pain, mental alertness, cognitive efficiency, and fine motor function for six months” with the results to be used as primary efficacy data.
The partnership between Clinvest and PHT has been positive so far. “We
“ePRO is more than digitized paper diaries,” said Phil Lee, PHT president and CEO. “Assessing a treatment’s ability to enhance or prohibit reduction of cognitive processing efficiency is a rapidly emerging center of study in the pharmaceutical industry… We are privileged to be working with Clinvest on
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


















